{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:43:40Z","timestamp":1748587420711,"version":"3.40.5"},"reference-count":23,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"DOI":"10.2340\/actadv.v105.42576","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:02:27Z","timestamp":1747112547000},"page":"adv42576","source":"Crossref","is-referenced-by-count":1,"title":["Olanzapine-induced Drug Reaction with Eosinophilia and Systemic Symptoms: Case Report and Review of the Literature"],"prefix":"10.2340","volume":"105","author":[{"given":"Katrin","family":"Ickrath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Kneitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Stoevesandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"110704","doi-asserted-by":"crossref","unstructured":"Awad A, Goh MS, Trubiano JA. Drug reaction with eosinophilia and systemic symptoms: a systematic review. J Allergy Clin Immunol Pract 2023; 11: 1856\u20131868.","DOI":"10.1016\/j.jaip.2023.02.035"},{"key":"110705","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaip.2023.02.035","DOI":"10.1016\/j.jaip.2023.02.035"},{"key":"110706","doi-asserted-by":"crossref","unstructured":"Hansen E, Gallardo M, Yan A, Mital R, Jolley D, McFeeters J, et al. Risk assessment of drugs associated with DRESS syndrome based on publication frequency: a systematic review. J Am Acad Dermatol 2024; 91: 962\u2013966.","DOI":"10.1016\/j.jaad.2024.06.081"},{"key":"110707","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2024.06.081","DOI":"10.1016\/j.jaad.2024.06.081"},{"key":"110708","doi-asserted-by":"crossref","unstructured":"Raz A, Bergman R, Eilam O, Yungerman T, Hayek T. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 2001; 321: 156\u2013158.","DOI":"10.1097\/00000441-200102000-00008"},{"key":"110709","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/00000441-200102000-00008","DOI":"10.1097\/00000441-200102000-00008"},{"key":"110710","doi-asserted-by":"crossref","unstructured":"Penchilaiya V, Kuppili PP, Preeti K, Bharadwaj B. DRESS syndrome: addressing the drug hypersensitivity syndrome on combination of sodium valproate and olanzapine. Asian J Psychiatr 2017; 28: 175\u2013176.","DOI":"10.1016\/j.ajp.2017.05.015"},{"key":"110711","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ajp.2017.05.015","DOI":"10.1016\/j.ajp.2017.05.015"},{"key":"110712","doi-asserted-by":"crossref","unstructured":"Bixby AL, Goldsborough S, Iuppa A, LeBlanc A, Schultz HE, VandenBerg A. Successful use of carbamazepine in a patient with drug rash with eosinophilia and systemic symptoms. Ment Health Clin 2019; 9: 331\u2013335.","DOI":"10.9740\/mhc.2019.09.331"},{"key":"110713","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.9740\/mhc.2019.09.331","DOI":"10.9740\/mhc.2019.09.331"},{"key":"110714","doi-asserted-by":"crossref","unstructured":"Sogo A, Horiuchi H, Ueda T, Miyazaki H, Furuya R. Early-onset drug hypersensitivity syndrome in a man with pneumonia due to pre-sensitization to olanzapine. Cureus 2022; 14: e26374.","DOI":"10.7759\/cureus.26374"},{"key":"110715","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.7759\/cureus.26374","DOI":"10.7759\/cureus.26374"},{"key":"110716","doi-asserted-by":"crossref","unstructured":"Sohi MK, Towne D, Mogallapu R, Chalia A, Ang-Rabanes M. A Case of olanzapine-induced cutaneous eruption. Am J Case Rep 2023; 24: e941379.","DOI":"10.12659\/AJCR.941379"},{"key":"110717","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.12659\/AJCR.941379","DOI":"10.12659\/AJCR.941379"},{"key":"110718","doi-asserted-by":"crossref","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169: 1071\u20131080.","DOI":"10.1111\/bjd.12501"},{"key":"110719","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.12501","DOI":"10.1111\/bjd.12501"},{"key":"110720","unstructured":"U.S. Food and Drug Administration (FDA). Drug Safety Communication: FDA warns about rare but serious skin reactions with mental health drug olanzapine (Zyprexa, Zyprexa Zydis, Zyprexa Relprevv, and Symbyax). 2016. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-rare-serious-skin-reactions-mental-health-drug"},{"key":"110721","doi-asserted-by":"crossref","unstructured":"Teo YX, Friedmann PS, Polak ME, Ardern-Jones MR. Utility and safety of skin tests in drug reaction with eosinophilia and systemic symptoms (DRESS): a systematic review. J Allergy Clin Immunol Pract 2023; 11: 481\u2013491e5.","DOI":"10.1016\/j.jaip.2022.09.011"},{"key":"110722","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaip.2022.09.011","DOI":"10.1016\/j.jaip.2022.09.011"},{"key":"110723","doi-asserted-by":"crossref","unstructured":"Cordoba S, Navarro-Vidal B, Martinez-Moran C, Borbujo J. Reactivation of skin lesions after patch testing to investigate drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Actas Dermosifiliogr 2016; 107: 781\u2013783.","DOI":"10.1016\/j.adengl.2016.08.015"},{"key":"110724","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.adengl.2016.08.015","DOI":"10.1016\/j.adengl.2016.08.015"},{"key":"110725","doi-asserted-by":"crossref","unstructured":"Teo YX, Ardern-Jones MR. Reactivation of drug reaction with eosinophilia and systemic symptoms with ranitidine patch testing. Contact Dermatitis 2021; 84: 278\u2013279.","DOI":"10.1111\/cod.13733"},{"key":"110726","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/cod.13733","DOI":"10.1111\/cod.13733"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/42576\/50069","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/42576\/50069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:02:35Z","timestamp":1747112555000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/42576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":23,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.42576","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,12]]}}}